MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Molecular Pharmacology Fast Forward
First published on January 24, 2006; DOI: 10.1124/mol.105.018507

0026-895X/06/6904-1242-1250$20.00
Mol Pharmacol 69:1242-1250, 2006

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.105.018507v1
69/4/1242    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Neubauer, H. A.
Right arrow Articles by Wiborg, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Neubauer, H. A.
Right arrow Articles by Wiborg, O.
Original Article

Dissection of an Allosteric Mechanism on the Serotonin Transporter: A Cross-Species Study

Henrik Amtoft Neubauer, Carsten Gram Hansen, and Ove Wiborg

Laboratory of Molecular Neurobiology, Centre for Basic Psychiatric Research, Aarhus Psychiatric University Hospital, Risskov, Denmark

Abstract

The serotonin transporter (SERT), which belongs to a family of sodium/chloride-dependent transporters, is the major pharmacological target in the treatment of several clinical disorders, including depression and anxiety. Interaction with a low-affinity allosteric site on SERT modulates the ligand affinity at the high-affinity binding site. Serotonin (5-hydroxytryptamine) and certain SERT inhibitors possess affinity for both sites. In the present study, we report the characterization of a severely attenuated allosteric mechanism at the recently cloned chicken serotonin transporter (gSERT). A cross-species chimera study was performed, followed by species scanning mutagenesis. Residues important for the allosteric mechanism were mapped to the C-terminal part of SERT containing the transmembrane domains 10 to 12. We identified nine residues located in four distinct amino acid segments. The contribution of each segment and individual residues was investigated. Consequently, a gSERT mutant with a restored allosteric mechanism, as well as a human SERT (hSERT) mutant with a severely attenuated allosteric mechanism, was generated. The nine residues confer a functional allosteric mechanism for different combinations of ligands, suggesting that they contribute to a general allosteric mechanism at SERT. The finding of an allosteric mechanism at SERT is likely to be of physiological importance, in that serotonin was also found to act as an allosteric effector at duloxetine, RTI-55 and (S)-citalopram. Furthermore, the allosteric potency of 5-HT was found to be conserved for both hSERT and gSERT.

Received August 29, 2005; accepted January 24, 2006

Address correspondence to: Ove Wiborg, Laboratory of Molecular Neurobiology, Centre for Basic Psychiatric Research, Aarhus Psychiatric University Hospital, Skovagervej 2, DK-8240 Risskov, Denmark. E-mail: owiborg{at}post.tele.dk




This article has been cited by other articles:


Home page
 Mol. Pharmacol.Home page
T. Beuming, L. Shi, J. A. Javitch, and H. Weinstein
A Comprehensive Structure-Based Alignment of Prokaryotic and Eukaryotic Neurotransmitter/Na+ Symporters (NSS) Aids in the Use of the LeuT Structure to Probe NSS Structure and Function
Mol. Pharmacol., November 1, 2006; 70(5): 1630 - 1642.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics